Zerumbone inhibits tumor angiogenesis via NF-κB in gastric cancer

Tsuboi,Ken; Matsuo,Yoichi; Shamoto,Tomoya; Shibata,Takahiro; Koide,Shuji; Morimoto,Mamoru; Guha,Sushovan; Sung,Bokyung; Aggarwal,Bharat  B.; Takahashi,Hiroki; Takeyama,Hiromitsu

doi:10.3892/or.2013.2842

Zerumbone inhibits tumor angiogenesis via NF-κB in gastric cancer

Authors:
- Ken Tsuboi
- Yoichi Matsuo
- Tomoya Shamoto
- Takahiro Shibata
- Shuji Koide
- Mamoru Morimoto
- Sushovan Guha
- Bokyung Sung
- Bharat B. Aggarwal
- Hiroki Takahashi
- Hiromitsu Takeyama
View Affiliations

Affiliations: Department of Gastroenterological Surgery, Nagoya City University Graduate School of Medical Sciences, Nagoya, Japan, Division of Gastroenterology, Hepatology and Nutrition, UTH-Medical School and Health Science Center at Houston, Houston, TX, USA, Cytokine Research Laboratory, Department of Experimental Therapeutics, The University of Texas M.D. Anderson Cancer Center, Houston, TX, USA
Published online on: November 11, 2013 https://doi.org/10.3892/or.2013.2842
Pages: 57-64

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Zerumbone derived from a subtropical ginger, Zingiber zerumbet Smith, was previously reported to have antitumor growth and anti-inflammatory properties in some types of cancer. However, the effects of zerumbone against cancer angiogenesis have not been fully elucidated. In this study, we clarified the role of zerumbone in gastric cancer angiogenesis. We examined the expression of vascular endothelial growth factor (VEGF) in gastric cancer cell lines both in the basal state and following zerumbone treatment by real-time RT-PCR and enzyme-linked immunosorbent assay (ELISA). Changes in gastric cancer cell proliferation in response to zerumbone treatment were measured by WST-1 assay. Additionally, the effects of zerumbone on NF-κB activity were examined in AGS cells. Finally, the effects of zerumbone on angiogenesis in AGS cells were measured by in vitro angiogenesis assay in which human umbilical vein endothelial cells (HUVECs) and fibroblasts were cocultured with AGS cells. Among the 6 gastric cancer cell lines tested, AGS cells exhibited the highest expression of VEGF. Cell proliferation, VEGF expression and NF-κB activity in AGS cells were all significantly inhibited by zerumbone. Moreover, the tube formation area of HUVECs was increased by coculture with AGS cells, and this effect was inhibited by zerumbone. Both VEGF expression and NF-κB activity in AGS cells were reduced by treatment with zerumbone, thereby inhibiting angiogenesis. Thus, zerumbone may become a new anti-angiogenic and antitumor drug in the treatment of gastric cancer.

View Figures

View References

1	Ferlay J, Shin HR, Bray F, Forman D, Mathers C and Parkin DM: Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer. 13:2893–2917. 2010. View Article : Google Scholar : PubMed/NCBI
2	Jemal A, Bray F, Center MM, Ferlay J, Ward E and Forman D: Global cancer statistics. CA Cancer J Clin. 13:69–90. 2011. View Article : Google Scholar
3	Hartgrink HH, Jansen EP, van Grieken NC and van de Velde CJ: Gastric cancer. Lancet. 13:477–490. 2009. View Article : Google Scholar
4	Wagner AD, Grothe W, Haerting J, Kleber G, Grothey A and Fleig WE: Chemotherapy in advanced gastric cancer: a systematic review and meta-analysis based on aggregate data. J Clin Oncol. 24:2903–2909. 2006. View Article : Google Scholar : PubMed/NCBI
5	Matsuo Y, Sawai H, Funahashi H, et al: Enhanced angiogenesis due to inflammatory cytokines from pancreatic cancer cell lines and relation to metastatic potential. Pancreas. 28:344–352. 2004. View Article : Google Scholar : PubMed/NCBI
6	Tong Z, Kunnumakkara AB, Wang H, et al: Neutrophil gelatinase-associated lipocalin: a novel suppressor of invasion and angiogenesis in pancreatic cancer. Cancer Res. 68:6100–6108. 2008. View Article : Google Scholar : PubMed/NCBI
7	Matsuo Y, Sawai H, Ochi N, et al: Interleukin-1alpha secreted by pancreatic cancer cells promotes angiogenesis and its therapeutic implications. J Surg Res. 153:274–281. 2009. View Article : Google Scholar : PubMed/NCBI
8	Matsuo Y, Ochi N, Sawai H, et al: CXCL8/IL-8 and CXCL12/SDF-1alpha co-operatively promote invasiveness and angiogenesis in pancreatic cancer. Int J Cancer. 124:853–861. 2009. View Article : Google Scholar : PubMed/NCBI
9	Matsuo Y, Sawai H, Ma J, et al: IL-1alpha secreted by colon cancer cells enhances angiogenesis: the relationship between IL-1alpha release and tumor cells’ potential for liver metastasis. J Surg Oncol. 99:361–367. 2009.PubMed/NCBI
10	Matsuo Y, Sawai H, Ochi N, et al: Proteasome inhibitor MG132 inhibits angiogenesis in pancreatic cancer by blocking NF-kappaB activity. Dig Dis Sci. 55:1167–1176. 2010. View Article : Google Scholar : PubMed/NCBI
11	Matsuo Y, Raimondo M, Woodward TA, et al: CXC-chemokine/CXCR2 biological axis promotes angiogenesis in vitro and in vivo in pancreatic cancer. Int J Cancer. 125:1027–1037. 2009. View Article : Google Scholar : PubMed/NCBI
12	Matsuo Y, Campbell PM, Brekken RA, et al: K-Ras promotes angiogenesis mediated by immortalized human pancreatic epithelial cells through mitogen-activated protein kinase signaling pathways. Mol Cancer Res. 7:799–808. 2009. View Article : Google Scholar
13	Carmeliet P: Angiogenesis in health and disease. Nat Med. 9:653–660. 2003. View Article : Google Scholar : PubMed/NCBI
14	Ma J, Sawai H, Matsuo Y, et al: Interleukin-1alpha enhances angiogenesis and is associated with liver metastatic potential in human gastric cancer cell lines. J Surg Res. 148:197–204. 2008. View Article : Google Scholar : PubMed/NCBI
15	Maeda K, Chung YS, Ogawa Y, et al: Prognostic value of vascular endothelial growth factor expression in gastric carcinoma. Cancer. 77:858–863. 1996. View Article : Google Scholar : PubMed/NCBI
16	Maeda K, Kang SM, Onoda N, et al: Vascular endothelial growth factor expression in preoperative biopsy specimens correlates with disease recurrence in patients with early gastric carcinoma. Cancer. 86:566–571. 1999. View Article : Google Scholar
17	Kikuchi S, Obata Y, Yagyu K, et al: Reduced serum vascular endothelial growth factor receptor-2 (sVEGFR-2) and sVEGFR-1 levels in gastric cancer patients. Cancer Sci. 102:866–869. 2011. View Article : Google Scholar : PubMed/NCBI
18	Karayiannakis AJ, Syrigos KN, Polychronidis A, et al: Circulating VEGF levels in the serum of gastric cancer patients: correlation with pathological variables, patient survival, and tumor surgery. Ann Surg. 236:37–42. 2002. View Article : Google Scholar : PubMed/NCBI
19	Kim KK and Kim HB: Protein interaction network related to Helicobacter pylori infection response. World J Gastroenterol. 15:4518–4528. 2009. View Article : Google Scholar : PubMed/NCBI
20	Varro A, Noble PJ, Pritchard DM, et al: Helicobacter pylori induces plasminogen activator inhibitor 2 in gastric epithelial cells through nuclear factor-kappaB and RhoA: implications for invasion and apoptosis. Cancer Res. 64:1695–1702. 2004. View Article : Google Scholar
21	Keates S, Hitti YS, Upton M and Kelly CP: Helicobacter pylori infection activates NF-kappa B in gastric epithelial cells. Gastroenterology. 113:1099–1109. 1997. View Article : Google Scholar
22	Xiong HQ, Abbruzzese JL, Lin E, Wang L, Zheng L and Xie K: NF-kappaB activity blockade impairs the angiogenic potential of human pancreatic cancer cells. Int J Cancer. 108:181–188. 2004. View Article : Google Scholar : PubMed/NCBI
23	Beg AA and Baldwin AS Jr: The I kappa B proteins: multifunctional regulators of Rel/NF-kappa B transcription factors. Genes Dev. 7:2064–2070. 1993. View Article : Google Scholar : PubMed/NCBI
24	Verma IM, Stevenson JK, Schwarz EM, Van Antwerp D and Miyamoto S: Rel/NF-kappa B/I kappa B family: intimate tales of association and dissociation. Genes Dev. 9:2723–2735. 1995. View Article : Google Scholar : PubMed/NCBI
25	Nam SY, Ko YS, Jung J, et al: A hypoxia-dependent upregulation of hypoxia-inducible factor-1 by nuclear factor-κB promotes gastric tumour growth and angiogenesis. Br J Cancer. 104:166–174. 2011.
26	Nakata W, Hayakawa Y, Nakagawa H, et al: Anti-tumor activity of the proteasome inhibitor bortezomib in gastric cancer. Int J Oncol. 39:1529–1536. 2011.PubMed/NCBI
27	Caballero-Velázquez T, López-Corral L, Encinas C, et al: Phase II clinical trial for the evaluation of bortezomib within the reduced intensity conditioning regimen (RIC) and post-allogeneic transplantation for high-risk myeloma patients. Br J Haematol. 162:474–482. 2013.
28	Gupta SC, Kim JH, Prasad S, et al: Regulation of survival, proliferation, invasion, angiogenesis, and metastasis of tumor cells through modulation of inflammatory pathways by nutraceuticals. Cancer Metastasis Rev. 29:405–434. 2010. View Article : Google Scholar : PubMed/NCBI
29	Yob NJ, Jofrry SM, Affandi MM, et al: Zingiber zerumbet (L.) Smith: a review of its ethnomedicinal, chemical, and pharmacological uses. Evid Based Complement Alternat Med. 2011:5432162011.PubMed/NCBI
30	Murakami A, Takahashi D, Kinoshita T, et al: Zerumbone, a Southeast Asian ginger sesquiterpene, markedly suppresses free radical generation, proinflammatory protein production, and cancer cell proliferation accompanied by apoptosis: the alpha, beta-unsaturated carbonyl group is a prerequisite. Carcinogenesis. 23:795–802. 2002. View Article : Google Scholar
31	Sung B, Jhurani S, Ahn KS, et al: Zerumbone down-regulates chemokine receptor CXCR4 expression leading to inhibition of CXCL12-induced invasion of breast and pancreatic tumor cells. Cancer Res. 68:8938–8944. 2008. View Article : Google Scholar : PubMed/NCBI
32	Yodkeeree S, Sung B, Limtrakul P and Aggarwal BB: Zerumbone enhances TRAIL-induced apoptosis through the induction of death receptors in human colon cancer cells: evidence for an essential role of reactive oxygen species. Cancer Res. 69:6581–6589. 2009. View Article : Google Scholar
33	Kirana C, McIntosh GH, Record IR and Jones GP: Antitumor activity of extract of Zingiber aromaticum and its bioactive sesquiterpenoid zerumbone. Nutr Cancer. 45:218–225. 2003.
34	Kim M, Miyamoto S, Yasui Y, Oyama T, Murakami A and Tanaka T: Zerumbone, a tropical ginger sesquiterpene, inhibits colon and lung carcinogenesis in mice. Int J Cancer. 124:264–271. 2009. View Article : Google Scholar : PubMed/NCBI
35	Xian M, Ito K, Nakazato T, et al: Zerumbone, a bioactive sesquiterpene, induces G2/M cell cycle arrest and apoptosis in leukemia cells via a Fas- and mitochondria-mediated pathway. Cancer Sci. 98:118–126. 2007. View Article : Google Scholar : PubMed/NCBI
36	Huang GC, Chien TY, Chen LG and Wang CC: Antitumor effects of zerumbone from Zingiber zerumbet in P-388D1 cells in vitro and in vivo. Planta Med. 71:219–224. 2005. View Article : Google Scholar : PubMed/NCBI
37	Sakinah SA, Handayani ST and Hawariah LP: Zerumbone induced apoptosis in liver cancer cells via modulation of Bax/Bcl-2 ratio. Cancer Cell Int. 7:42007. View Article : Google Scholar : PubMed/NCBI
38	Sung B, Murakami A, Oyajobi BO and Aggarwal BB: Zerumbone abolishes RANKL-induced NF-κB activation, inhibits osteoclastogenesis, and suppresses human breast cancer-induced bone loss in athymic nude mice. Cancer Res. 69:1477–1484. 2009.PubMed/NCBI
39	Takada Y, Murakami A and Aggarwal BB: Zerumbone abolishes NF-κB and IκBα kinase activation leading to suppression of antiapoptotic and metastatic gene expression, upregulation of apoptosis, and downregulation of invasion. Oncogene. 24:6957–6969. 2005.
40	Chen D, Frezza M, Schmitt S, Kanwar J and Dou QP: Bortezomib as the first proteasome inhibitor anticancer drug: current status and future perspectives. Curr Cancer Drug Targets. 11:239–253. 2011. View Article : Google Scholar : PubMed/NCBI
41	Aggarwal BB, Van Kuiken ME, Iyer LH, Harikumar KB and Sung B: Molecular targets of nutraceuticals derived from dietary spices: potential role in suppression of inflammation and tumorigenesis. Exp Biol Med. 234:825–849. 2009. View Article : Google Scholar : PubMed/NCBI
42	Li-Weber M: New therapeutic aspects of flavones: the anticancer properties of Scutellaria and its main active constituents Wogonin, Baicalein and Baicalin. Cancer Treat Rev. 35:57–68. 2009. View Article : Google Scholar : PubMed/NCBI
43	Harikumar KB, Sung B, Tharakan ST, et al: Sesamin manifests chemopreventive effects through the suppression of NF-kappa B-regulated cell survival, proliferation, invasion, and angiogenic gene products. Mol Cancer Res. 8:751–761. 2010. View Article : Google Scholar
44	Bhuiyan NI, Chowdhury JU and Begum J: Chemical investigation of the leaf and rhizome essential oils of Zingiber zerumbet (L.) Smith from Bangladesh. Bangladesh J Pharmacol. 4:9–12. 2009.
45	Zakaria ZA, Mohamad AS, Chear CT, Wong YY, Israf zDA and Sulaiman MR: Antiinflammatory and antinociceptive activities of Zingiber zerumbet methanol extract in experimental model systems. Med Princ Pract. 19:287–294. 2010.PubMed/NCBI
46	Zakaria ZA, Mohamad AS, Ahmad MS, et al: Preliminary analysis of the anti-inflammatory activity of essential oil of Zingiber zerumbet. Biol Res Nurs. 13:425–432. 2011. View Article : Google Scholar : PubMed/NCBI
47	Tushar, Basak S, Sarma GC and Rangan L: Ethnomedical uses of Zingiberaceous plants of Northeast India. J Ethnopharmacol. 132:286–296. 2010. View Article : Google Scholar : PubMed/NCBI
48	Somchit MN and Shukriyah MHN: Antiinflammatory property of ethanol and water extracts of Zingiber zerumbet. Indian J Pharmacol. 35:181–182. 2003.
49	Somchit MN, Shukriyah MHN, Bustamam AA and Zuraini A: Anti-pyretic and analgesic activity of Zingiber zerumbet. Int J Pharmacol. 1:277–280. 2005. View Article : Google Scholar
50	Sulaiman MR, Tengku Mohamad TA, Shaik Mossadeq WM, et al: Antinociceptive activity of the essential oil of Zingiber zerumbet. Planta Med. 76:107–112. 2010. View Article : Google Scholar : PubMed/NCBI
51	Jantan IB, Yassin MS, Chin CB, Chen LL and Sim NL: Antifungal activity of the essential oils of nine Zingiberaceae species. Pharm Biol. 41:392–397. 2003. View Article : Google Scholar
52	Voravuthikunchai SP, Phongpaichit S and Subhadhirasakul S: Evaluation of antibacterial activities of medicinal plants widely used among AIDS patients in Thailand. Pharm Biol. 43:701–706. 2005. View Article : Google Scholar
53	Voravuthikunchai SP, Limsuwan S, Supapol O and Subhadhirasakul S: Antibacterial activity of extracts from family Zingiberaceae against foodborne pathogens. J Food Safety. 26:325–334. 2005. View Article : Google Scholar
54	Phongpaichit S, Vuddhakul V, Subhadhirasakul S and Wattanapiromsakul C: Evaluation of the antimycobacterial activity of extracts from plants used as self-medication by AIDS patients in Thailand. Pharm Biol. 44:71–75. 2006. View Article : Google Scholar
55	Tewtrakul S and Subhadhirasakul S: Anti-allergic activity of some selected plants in the Zingiberaceae family. J Ethnopharmacol. 109:535–538. 2007. View Article : Google Scholar : PubMed/NCBI
56	Murakami A and Ohigashi H: Targeting NOX, INOS and COX-2 in inflammatory cells: chemoprevention using food phytochemicals. Int J Cancer. 121:2357–2363. 2007. View Article : Google Scholar : PubMed/NCBI
57	Murakami A, Shigemori T and Ohigashi H: Zingiberaceous and citrus constituents, 10-acetoxychavicol acetate, zerumbone, auraptene, and nobiletin, suppress lipopolysaccharide-induced cyclooxygenase-2 expression in RAW264.7 murine macrophages through different modes of action. J Nutr. 135(Suppl 12): 2987–2992. 2005.
58	Maeda S, Yoshida H, Ogura K, et al: H. pylori activates NF-kappaB through a signaling pathway involving IkappaB kinases, NF-kappaB-inducing kinase, TRAF2, and TRAF6 in gastric cancer cells. Gastroenterology. 119:97–108. 2000. View Article : Google Scholar
59	Lamb A and Chen LF: Role of the Helicobacter pylori-induced inflammatory response in the development of gastric cancer. J Cell Biochem. 114:491–497. 2013.
60	Yin Y, Si X, Gao Y, Gao L and Wang J: The nuclear factor-κB correlates with increased expression of interleukin-6 and promotes progression of gastric carcinoma. Oncol Rep. 29:34–38. 2013.